Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
0.4444
-0.0278 (-5.89%)
At close: May 30, 2025, 4:00 PM
0.4525
+0.0081 (1.82%)
After-hours: May 30, 2025, 7:59 PM EDT
Silo Pharma Revenue
Silo Pharma had revenue of $18.03K in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $72.10K. In the year 2024, Silo Pharma had annual revenue of $72.10K.
Revenue (ttm)
$72.10K
Revenue Growth
n/a
P/S Ratio
25.18
Revenue / Employee
$24,034
Employees
3
Market Cap
3.20M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SILO News
- 9 days ago - Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15 - GlobeNewsWire
- 14 days ago - Silo Pharma Announces Closing of $2 Million Public Offering - GlobeNewsWire
- 15 days ago - Silo Pharma Announces Pricing of $2 Million Public Offering - GlobeNewsWire
- 16 days ago - Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15 - GlobeNewsWire
- 16 days ago - Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories - GlobeNewsWire
- 4 weeks ago - Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study - GlobeNewsWire
- 4 weeks ago - Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug - GlobeNewsWire
- 2 months ago - Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment - GlobeNewsWire